ELEVATION ONCOLOGY INC (ELEV)

US28623U1016 - Common Stock

3.7  -0.12 (-3.14%)

Fundamental Rating

2

Overall ELEV gets a fundamental rating of 2 out of 10. We evaluated ELEV against 588 industry peers in the Biotechnology industry. While ELEV seems to be doing ok healthwise, there are quite some concerns on its profitability. ELEV is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELEV had negative earnings in the past year.
In the past year ELEV has reported a negative cash flow from operations.
In the past 5 years ELEV always reported negative net income.
In the past 5 years ELEV always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of ELEV (-51.31%) is comparable to the rest of the industry.
ELEV has a Return On Equity (-83.40%) which is in line with its industry peers.
Industry RankSector Rank
ROA -51.31%
ROE -83.4%
ROIC N/A
ROA(3y)-57.89%
ROA(5y)-100.9%
ROE(3y)-100.07%
ROE(5y)-155.16%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELEV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for ELEV has been increased compared to 1 year ago.
Compared to 1 year ago, ELEV has a worse debt to assets ratio.

2.2 Solvency

ELEV has an Altman-Z score of -0.19. This is a bad value and indicates that ELEV is not financially healthy and even has some risk of bankruptcy.
ELEV has a Altman-Z score of -0.19. This is comparable to the rest of the industry: ELEV outperforms 58.36% of its industry peers.
ELEV has a Debt/Equity ratio of 0.55. This is a neutral value indicating ELEV is somewhat dependend on debt financing.
ELEV's Debt to Equity ratio of 0.55 is on the low side compared to the rest of the industry. ELEV is outperformed by 73.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Altman-Z -0.19
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 21.22 indicates that ELEV has no problem at all paying its short term obligations.
ELEV has a Current ratio of 21.22. This is amongst the best in the industry. ELEV outperforms 95.90% of its industry peers.
ELEV has a Quick Ratio of 21.22. This indicates that ELEV is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ELEV (21.22) is better than 95.90% of its industry peers.
Industry RankSector Rank
Current Ratio 21.22
Quick Ratio 21.22

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.59% over the past year.
EPS 1Y (TTM)62.59%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q76.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, ELEV will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.10% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.12%
EPS Next 2Y18.69%
EPS Next 3Y7.78%
EPS Next 5Y12.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELEV. In the last year negative earnings were reported.
Also next year ELEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.69%
EPS Next 3Y7.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELEV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELEVATION ONCOLOGY INC

NASDAQ:ELEV (5/3/2024, 7:00:01 PM)

3.7

-0.12 (-3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap180.00M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.31%
ROE -83.4%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 21.22
Quick Ratio 21.22
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)62.59%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y43.12%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y